In Australia, NovaTears® eye drops are available on the Pharmaceutical Benefits Scheme (PBS) from now on

  • Using innovative new technology, NovaTears® effectively establishes a new class of treatment for Evaporative Dry Eye.
  • Free from preservatives, water and phosphates, and can be used for up to six months after opening.

Heidelberg, Germany – Sep 12, 2018 – Novaliq GmbH, a specialty pharmaceutical company with the first water-free technology platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, is the manufacturer of NovaTears®, a novel topical treatment of dry eye disease (DED) and meibomian gland dysfunction (MGD).

AFT Pharmaceuticals Ltd (AFT) commercializes NovaTears® across Australasia. AFT just announced that NovaTears®, its new preservative-free eye lubricant and tear film stabiliser for the treatment of Evaporative Dry Eye (EDE), has been listed on the Australian Pharmaceutical Benefits Scheme (PBS) from 1st September 2018.
In Australia, NovaTears® is currently available over-the-counter from pharmacies, but from September 1st it can also be prescribed on the PBS, enabling more dry eye patients to benefit from using it.

Research has shown that EDE is by far the most common type of Dry Eye Disease (DED), impacting approximately 86% of DED sufferers (50% experiencing EDE alone and a further 36% experiencing a combination of EDE and aqueous deficiency).i

“NovaTears® is a new class of dry eye therapy based on patented EyeSol® technology, which can provide relief for EDE sufferers, and fulfil a significant patient need,“ explains Dr Hartley Atkinson, pharmacologist and CEO of AFT Pharmaceuticals. “It is long-lasting and spreads very easily across the eye, providing relief without blurred vision, stinging or burning.”
Being water-free is one of the major benefits of NovaTears®, as it means there is no microbial growth possible in the solution and allows for the delivery of preservative-free drops in a convenient multi-dose bottle. NovaTears® also has a much smaller droplet size (ca. 4x smaller) than traditional water-based eye drops, which minimises spill-over.

“Clinical studies of Evaporative Dry Eye Disease and Meibomian Gland Dysfunction patients have shown significant improvement in objective signs and subjective symptoms after using NovaTears® ii”, continues Dr Atkinson. “We are very pleased to see NovaTears® listed on the PBS, allowing greater access to EDE sufferers, particularly those who are sensitive to preservatives.”
“With the positive PBS listing of NovaTears®, more dry eye patients can benefit from this new and highly efficacious treatment for Dry Eye Disease,” said Christian Roesky, CEO of Novaliq GmbH. I am confident that patients will welcome this breakthrough.”

About AFT Pharmaceuticals
AFT founded in 1997 is an Auckland, New Zealand-based pharmaceuticals company operating in Australia, New Zealand and the Pacific Islands. AFT has been listed on the Australian [ASX] and New Zealand [NZX] stock exchanges since December 2015 and has significant local sales operations in Australasia together with R&D activities in pain, orphan drugs and medical devices.

Sources
i) Lemp, M.A., Crews, L.A., Bron, A.J., Foulks, G.N. and Sullivan, B.D., 2012. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea, 31(5), pp.472-478.
ii) Steven, Philipp, et al. “Semifluorinated Alkane Eye Drops for Treatment of Dry Eye Disease – A Prospective, Multicenter Noninterventional Study.” Journal of Ocular Pharmacology and Therapeutics 31 (8), 498-503(2015) and Steven, Philipp, et al. “Semifluorinated Alkane Eye Drops for Treatment of Dry Eye Disease Due to Meibomian Gland Disease.” Journal of Ocular Pharmacology and Therapeutics. 33(9), 678-685(2017). Sponsored by Novaliq GmbH.

Novaliq Announces More than 50% Patients Enrolled in CyclASol® Phase 3 Dry Eye Disease Trial ESSENCE-2

  • Topline results expected in 2nd half 2021; 475 out of a 834 target patients randomized in ESSENCE-2
  • Enrollment for 12-month safety extension trial (ESSENCE-2 OLE) completed
  • Phase 2B/3 Trial ESSENCE-1 Published in Cornea: The Journal of Cornea and External Disease
Heidelberg and Cambridge, MA – April 28, 2021 – Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced that the second Phase 3 clinical trial evaluating CyclASol® to treat the signs and symptoms of dry eye disease (DED) has randomized more than 50% out of 834 targeted patients, with top-line results expected in the 2nd half of 2021.

Betaliq Initiates Enrollment of Phase 2 Clinical Trial For The Treatment of Glaucoma or Ocular Hypertension

Betaliq Initiates Enrollment of Phase 2 Clinical Trial Investigating BTQ-1901-A, BTQ 1901 B and BTQ-1902 For The Treatment of Glaucoma or Ocular Hypertension
TAMPA, FL, UNITED STATES, April 20,2021 /EINPresswire.com/ — Betaliq, Inc., a clinical-stage ophthalmic company focused on developing therapies for the treatment of glaucoma, today announced enrollment of the first subject in their Phase 2 clinical trial. Betaliq’s pipeline consists of two preservative-free and water-free glaucoma drug candidates based on Novaliq GmbH’s EyeSol® technology. EyeSol is the worldwide first and only water-free technology for topical ophthalmology products. Two EyeSol based ophthalmic products are currently approved in Europe and Australia and two active INDs are in late-stage development in the United States.

Partner Bausch + Lomb Announces Statistically Significant Topline Results from the First Phase 3 Trial of NOV03

All Primary and Secondary Endpoints Were Achieved
LAVAL, Quebec, and HEIDELBERG, Germany, April 13, 2021 – Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”), and Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, today announced statistically significant topline data from the first Phase 3 trial (GOBI trial) evaluating the investigational drug NOV03 (perfluorohexyloctane) as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with meibomian gland dysfunction (MGD).

Bausch + Lomb Completes Enrollment of first Phase 3 Study for Nov03 (perfluorohexyloctane)

LAVAL, Quebec, and HEIDELBERG, Jan. 20 2021 – Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) and Bausch + Lomb, its leading global eye health business, and Novaliq GmbH, a pharmaceutical company focusing on first- and best-in-class ocular therapeutics, announced today that Bausch Health has acquired an exclusive license for the commercialization and development in the United States and Canada of the investigational treatment NOV03 (perfluorohexyloctane), a first-in-class investigational drug with a novel mechanism of action to treat Dry Eye Disease (DED) associated with Meibomian gland dysfunction (MGD).

Novaliq Announces First Patient Randomized in the Phase 3 trial ESSENCE-2 of CyclASol® Topical Ophthalmic Solution for the Treatment of Dry Eye Disease

Novaliq Announces First Patient Randomized in the Phase 3 trial ESSENCE-2 of CyclASol® Topical Ophthalmic Solution for the Treatment of Dry Eye Disease
  • ESSENCE-2 is the second registration trial to complete the clinical development of CyclASol® as agreed with U.S. Food and Drug Administration (FDA)
  • Designed to replicate efficacy demonstrated in previous phase 2/3 ESSENCE-1 trial
  • Topline data expected in 2nd half 2021